Mesoblast (MESO) Change in Cash (2014 - 2025)
Mesoblast (MESO) posted Change in Cash of $22.5 million for Q2 2023, up 219.88% sequentially from -$18.8 million in Q1 2023, and up 239.23% YoY from $6.6 million in Q2 2022.
Analysis
Mesoblast (MESO) Change in Cash (2014 - 2025) Analysis & Trends
Mesoblast has reported Change in Cash for 8 years, with the latest figure at $22.5 million in Q2 2023.
- Quarterly Change in Cash rose 239.23% year-over-year to $22.5 million in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $11.0 million (up 114.55% YoY) and the FY2025 annual result came in at $97.5 million, up 1274.3% from the prior year.
- Change in Cash grew to $22.5 million in Q2 2023 per MESO's latest filing, from -$18.8 million in the prior quarter.
- Over five years, Change in Cash peaked at $81.0 million in Q1 2021 and troughed at -$31.7 million in Q4 2020.
- A 5-year average of -$439500.0 and a median of -$18.3 million in 2022 frame the typical range for Change in Cash.
- The sharpest annual moves came in 2020 and 2021: Change in Cash plunged 208.58% in 2020, then soared 491.98% in 2021.
- Over 5 years, Change in Cash stood at $46.4 million in 2019, then sank by 168.33% to -$31.7 million in 2020, then jumped by 33.25% to -$21.2 million in 2021, then rose by 12.66% to -$18.5 million in 2022, then soared by 221.59% to $22.5 million in 2023.
- According to Business Quant data, Change in Cash over the past three periods registered $22.5 million, -$18.8 million, and -$18.5 million for Q2 2023, Q1 2023, and Q4 2022 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 649.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -504.60 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -185.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 374.50 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 427.25 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -2.94 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 225.59 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -37.42 Mn |
| 10 | Mesoblast | 2.24 Bn | 2.14 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2025 | 161.55 Mn |
| Jun 30, 2023 | -1.22 Mn |
| Mar 31, 2023 | 48.80 Mn |
| Dec 31, 2022 | 67.62 Mn |
| Sep 30, 2022 | 1.34 Mn |
| Jun 30, 2022 | 120.17 Mn |
| Mar 31, 2022 | 76.76 Mn |
| Dec 31, 2021 | 94.85 Mn |
| Sep 30, 2021 | 1.84 Mn |
| Jun 30, 2021 | 136.88 Mn |
| Mar 31, 2021 | 80.96 Mn |
| Dec 31, 2020 | -31.73 Mn |
| Sep 30, 2020 | -21.71 Mn |
| Jun 30, 2020 | 129.33 Mn |
| Mar 31, 2020 | 9.94 Mn |
| Dec 31, 2019 | 30.59 Mn |
| Sep 30, 2019 | -15.85 Mn |
| Jun 30, 2019 | 50.43 Mn |
| Mar 31, 2019 | -6.69 Mn |
| Dec 31, 2018 | 55.28 Mn |